High grade gliomas are a group of aggressive malignant intrinsic brain tumors, typically WHO grade III and IV, including anaplastic gliomas and glioblastoma. They are associated with high recurrence rates and poor prognosis despite multimodal therapy. Management generally includes surgery plus chemoradiation.
Johnson & Johnson invests over $1 billion in a new Pennsylvania cell therapy manufacturing facility for cancer and neurological diseases. The expansion addresses growing demand for advanced therapies while highlighting workforce training challenges in GMP environments. Other developments include new cell line technology for viral vector production and CRISPR-edited CAR-T manufacturing partnerships.
Cellectar Biosciences said it will report full-year 2025 financial results and provide a corporate update on March 4, 2026. The company also shared conference call, webcast, and replay details.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07439172 |
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07346144 |
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma |
RECRUITING | PHASE1/PHASE2 |
| NCT07331064 |
Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor |
NOT_YET_RECRUITING | PHASE1 |
| NCT07210632 |
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) |
RECRUITING | EARLY_PHASE1 |
| NCT07061626 |
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07017816 |
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies. |
RECRUITING | EARLY_PHASE1 |
| NCT06740097 |
Feasibility of Aspirate Tissue Monitoring in Neuro-oncological Surgery |
RECRUITING | NA |
| NCT06607692 |
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). |
RECRUITING | PHASE1/PHASE2 |
| NCT00918281 |
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection |
COMPLETED | PHASE2 |
| NCT00743353 |
Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5 |
COMPLETED | EARLY_PHASE1 |
